Immunotherapy before and after surgery for stage III melanoma or throat cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two immunotherapy medicines given before surgery and again after surgery to help control the cancer and improve outcomes. It studies people with resectable (operable) stage III melanoma or certain stage III/IVA throat cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed stage III cutaneous melanoma, or stage III/IVA resectable throat cancer (oral cavity, tonsil area/oropharynx, voice box/larynx, or bottom of throat/hypopharynx).
- Your tumor must be measurable on scans and your doctors must believe it can be fully removed with curative-intent surgery.
- You must be able to provide tumor tissue from a biopsy or archived sample (and the tissue should not be previously irradiated).
- You must be 18 or older, and generally well enough to do daily activities (ECOG performance status 0–1).
- Your recent blood tests and organ function (kidneys, liver, blood counts) must meet study minimums.
- You cannot have certain past treatments soon before starting (including prior chemotherapy/targeted therapy/radiation within 2 weeks, or prior immune checkpoint therapy stopped due to severe side effects).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
This trial tests whether giving a combination of three immunotherapy drugs before surgery can help shrink melanoma and improve outcomes. It is for people whose melanoma can be surgically removed, and the goal is to see if this approach is safe and effective.
This trial tests whether a drug called pembrolizumab (Keytruda) can help people with advanced throat cancer avoid removal of the voice box. You may be eligible if you have a specific type of larynx or hypopharynx cancer that hasn't been treated with radiation or immunotherapy before.
This Phase 2 trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before curative surgery can improve outcomes for people with resectable, recurrent head and neck squamous cell cancer. It also studies how these treatments affect the tumor and immune response using required tissue and blood samples.
This trial tests a combination of two immunotherapy drugs (pembrolizumab and N-803) with or without special immune cells (PD-L1 t-haNK cells) before surgery for head and neck cancer. The goal is to see if this treatment can shrink the cancer or improve the outcome after surgery.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.